Clinical Trials | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The appointment is effective from May 01, 2023 for five years
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Subscribe To Our Newsletter & Stay Updated
